Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation.
OBJECTIVE
To report a case in which we treated cytomegalovirus retinitis using an intravitreal ganciclovir sustained-release device in a patient negative for the human immunodeficiency virus, with a history of myeloproliferative syndrome with myelofibrosis and profound immunosuppression after allogeneic bone marrow transplantation.


METHODS
Case report. Review of medical records and fundus photographs.


RESULTS
After the ganciclovir device was implanted, the cytomegalovirus retinitis did not progress, and visual acuity improved. We removed the device 9 months after implantation.


CONCLUSIONS
The ganciclovir sustained-release device may be useful for treating cytomegalovirus retinitis in patients without the acquired immunodeficiency syndrome who are profoundly immunosuppressed and fail conventional intravenous therapy. If immune suppression is of limited duration, the device can be removed.
McAuliffe
P F
PF
Department of Ophthalmology, New York Hospital, Cornell Medical Center, NY 10021, USA.
Hall
M J
MJ
Castro-Malaspina
H
H
Heinemann
M H
MH
D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000209:etiology; D004343:Drug Implants; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D007108:Immune Tolerance; D016867:Immunocompromised Host; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000628:therapy
D000998:Antiviral Agents; D004343:Drug Implants; D015774:Ganciclovir